Poxel S.A. (FRA:7PO)

Market Cap	14.78M +14.7%
Revenue (ttm)	7.66M +250.0%
Net Income	-13.66M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	448
Open	0.2635
Previous Close	0.2630
Day's Range	0.2635 - 0.2635
52-Week Range	0.1656 - 0.8030
Beta	n/a
RSI	46.15
Earnings Date	Mar 23, 2026

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7PO

Financial Performance

In 2024, Poxel's revenue was 6.64 million, an increase of 234.98% compared to the previous year's 1.98 million. Losses were -18.31 million, -47.83% less than in 2023.